The genomic landscape of response to EGFR blockade in colorectal cancer

Nature

Volumn 526, Issue 7572, 2015, Pages 263-267

  Bertotti, Andrea ^a,b,c   Papp, Eniko ^d   Jones, Siân ^e   Adleff, Vilmos ^d   Anagnostou, Valsamo ^d   Lupo, Barbara ^a,b   Sausen, Mark ^e   Phallen, Jillian ^d   Hruban, Carolyn A ^d   Tokheim, Collin ^f   Niknafs, Noushin ^f   Nesselbush, Monica ^e   Lytle, Karli ^e   Sassi, Francesco ^b   Cottino, Francesca ^b   Migliardi, Giorgia ^a,b   Zanella, Eugenia R ^a,b   Ribero, Dario ^g,m   Russolillo, Nadia ^g   Mellano, Alfredo ^b   Muratore, Andrea ^b   Paraluppi, Gianluca ^h   Salizzoni, Mauro ^a,h   Marsoni, Silvia ^b   Kragh, Michael ⁱ   Lantto, Johan ⁱ   Cassingena, Andrea ^j   Li, Qing Kay ^d   Karchin, Rachel ^d,f   Scharpf, Robert ^d   Sartore Bianchi, Andrea ^j   Siena, Salvatore ^j,k   Diaz, Luis A ^d,l   Trusolino, Livio ^a,b   Velculescu, Victor E ^d   more..

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Personal Genome Diagnostics   (United States)

^f Johns Hopkins University   (United States)

^g MAURIZIANO HOSPITAL   (Italy)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ Symphogen AS   (Denmark)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; INFIGRATINIB; PAN HER; PANITUMUMAB; SCH 772984; SELUMETINIB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P21;

ANTIBODY; CANCER; DISEASE TREATMENT; GENE EXPRESSION; GENOMICS; HORMONE; MUTATION; PROTEIN; PUBLIC HEALTH; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; EGFR GENE; ERBB2 GENE; EXOME; FEMALE; FGFR1 GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IRS2 GENE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MAP2K1 GENE; MOUSE; NONHUMAN; ONCOGENE K RAS; PDGFRA GENE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SOMATIC MUTATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLORECTAL NEOPLASMS; COPY NUMBER VARIATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; GENOMICS; HUMAN GENOME; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CETUXIMAB; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; EXOME; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MAP KINASE KINASE 1; MICE; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944079826     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14969     Document Type: Article

References (39)

1. Van Cutsem, E., Cervantes, A., Nordlinger, B. & Arnold, D. on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii1-iii9 (2014).
2. Diaz, L. A. Jr et al. Themolecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
3. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
4. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
5. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
6. Tol, J. et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur. J. Cancer 46, 1997-2009 (2010).
7. Sartore-Bianchi, A. et al. PIK3CAmutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851-1857 (2009).
8. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
9. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximabresistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
10. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFRdirected therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
11. Montagut, C. et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nature Med. 18, 221-223 (2012).
12. Bettegowda, C. et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
13. Diaz, L. A. Jr, Sausen, M., Fisher, G. A. & Velculescu, V. E. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget 4, 1856-1857 (2013).
14. Leary, R. J. et al. Integrated analysis of homozygous deletions, focalamplifications, andsequence alterations in breastandcolorectal cancers. Proc.Natl Acad. Sci.USA 105, 16224-16229 (2008).
15. Barber, T. D., Vogelstein, B., Kinzler, K. W. & Velculescu, V. E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004).
16. Moroni, M. et al. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann. Oncol. 16, 1848-1849 (2005).
17. Wesche, J., Haglund, K. & Haugsten, E. M. Fibroblast growth factors and their receptors in cancer. Biochem. J. 437, 199-213 (2011).
18. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708-710 (2003).
19. Dibb, N. J., Dilworth, S. M.&Mol, C. D.Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Rev. Cancer 4, 718-727 (2004).
20. Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524-5528 (2008).
21. Algars, A., Lintunen, M., Carpen, O., Ristamaki, R. & Sundstrom, J. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br. J. Cancer 105, 255-262 (2011).
22. Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 6, 279-286 (2005).
23. Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
24. Misale, S. et al. Blockade of EGFR andMEK intercepts heterogeneousmechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra226 (2014).
25. Zanella, E. R. et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci. Transl. Med. 7, 272ra212 (2015).
26. Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 5, 832-841 (2015).
27. Voigt,M. et al. Functionaldissectionof theepidermal growthfactor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 14, 1023-1031 (2012).
28. Koefoed, K. et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3, 584-595 (2011).
29. Pavlicek, A. et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol. Cancer Ther. 12, 2929-2939 (2013).
30. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
31. Siena, S. et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS One 8, e62264 (2013).
32. Galimi, F. et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin. Cancer Res. 17, 3146-3156 (2011).
33. Baralis, E., Bertotti, A., Fiori, A. & Grand, A. LAS: A software platform to support oncological data management. J. Med. Syst. 36 (Suppl. 1), S81-S90 (2012).
34. Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra253 (2015).
35. Needleman, S. B. & Wunsch, C. D. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48, 443-453 (1970).
36. Leary, R. J., Cummins, J., Wang, T. L. & Velculescu, V. E. Digital karyotyping. Nature Protocols 2, 1973-1986 (2007).
37. Jiao, Y. et al. Exome sequencing identifies frequent inactivatingmutations inBAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genet. 45, 1470-1473 (2013).
38. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
39. Kan, Z. et al. Diverse somaticmutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).